A Natural Small Molecule Harmine Inhibits Angiogenesis and Suppresses Tumour Growth through Activation of p53 in Endothelial Cells

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Dai, Fujun ^a   Chen, Yihua ^a   Song, Yajuan ^a   Huang, Li ^a   Zhai, Dong ^a   Dong, Yanmin ^a   Lai, Li ^a   Zhang, Tao ^a   Li, Dali ^a   Pang, Xiufeng ^a   Liu, Mingyao ^a,b   Yi, Zhengfang ^a  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOHEXIMIDE; HARMINE; PROTEIN MDM2; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE ARREST; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR MODEL; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; AORTA; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; COMET ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HALLUCINOGENS; HARMINE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOPRECIPITATION; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MDM2; RATS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84871661717     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052162     Document Type: Article

References (49)

1. Zhang L, Zhang J, Hu CQ, Cao J, Zhou XL, et al. (2009) Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction. Anti-Cancer Drugs 20: 416-424.
2. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, et al. (2002) Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8: 282-288.
3. Chen D, Zhang Z, Li M, Wang W, Li Y, et al. (2007) Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function. Oncogene 26: 5029-5037.
4. Song Y, Dai F, Zhai D, Dong Y, Zhang J,et al. Usnic acid inhibits breast tumor angiogenesis and growth by suppressing VEGFR2-mediated AKT and ERK1/2 signaling pathways. Angiogenesis 15: 421-432.
5. Teodoro JG, Evans SK, Green MR, (2007) Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med 85: 1175-1186.
6. Dameron KM, Volpert OV, Tainsky MA, Bouck N, (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582-1584.
7. Duda DG, Sunamura M, Lozonschi L, Yokoyama T, Yatsuoka T, et al. (2002) Overexpression of the p53-inducible brain-specific angiogenesis inhibitor 1 suppresses efficiently tumour angiogenesis. Br J Cancer 86: 490-496.
8. Li H, Lakshmikanth T, Carbone E, Selivanova G, (2012) A novel facet of tumor suppression by p53: Induction of tumor immunogenicity. Oncoimmunology 1: 541-543.
9. Kruse JP, Gu W, (2009) Modes of p53 regulation. Cell 137: 609-622.
10. Murray-Zmijewski F, Slee EA, Lu X, (2008) A complex barcode underlies the heterogeneous response of p53 to stress. Nat Rev Mol Cell Biol 9: 702-712.
11. Miyachi M, Kakazu N, Yagyu S, Katsumi Y, Tsubai-Shimizu S, et al. (2009) Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells. Clin Cancer Res 15: 4077-4084.
12. Zhang Q, Zeng SX, Zhang Y, Ding D, Ye Q, et al. (2012) A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53. EMBO Mol Med 4: 298-312.
13. Frost D, Meechoovet B, Wang T, Gately S, Giorgetti M, et al. (2011) beta-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites. PLoS One 6: e19264.
14. Hamsa TP, Kuttan G, (2010) Harmine inhibits tumour specific neo-vessel formation by regulating VEGF, MMP, TIMP and pro-inflammatory mediators both in vivo and in vitro. Eur J Pharmacol 649: 64-73.
15. Lala S, Pramanick S, Mukhopadhyay S, Bandyopadhyay S, Basu MK, (2004) Harmine: evaluation of its antileishmanial properties in various vesicular delivery systems. J Drug Target 12: 165-175.
16. Hudson JB, Graham EA, Towers GH, (1986) Antiviral effect of harmine, a photoactive beta-carboline alkaloid. Photochem Photobiol 43: 21-26.
17. Gockler N, Jofre G, Papadopoulos C, Soppa U, Tejedor FJ, et al. (2009) Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation. FEBS J 276: 6324-6337.
18. Cao MR, Li Q, Liu ZL, Liu HH, Wang W, et al. (2011) Harmine induces apoptosis in HepG2 cells via mitochondrial signaling pathway. Hepatobiliary Pancreat Dis Int 10: 599-604.
19. Bravman T, Bronner V, Lavie K, Notcovich A, Papalia GA, et al. (2006) Exploring "one-shot" kinetics and small molecule analysis using the ProteOn XPR36 array biosensor. Anal Biochem 358: 281-288.
20. Lai L, Liu J, Zhai D, Lin Q, He L, et al. (2012) Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor-2. Br J Pharmacol 165: 1084-1096.
21. Dong Y, Lu B, Zhang X, Zhang J, Lai L, et al. (2010) Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling pathway. Carcinogenesis 31: 2097-2104.
22. Olive PL, Banath JP, (2006) The comet assay: a method to measure DNA damage in individual cells. Nat Protoc 1: 23-29.
23. Yi ZF, Cho SG, Zhao H, Wu YY, Luo J, et al. (2009) A novel peptide from human apolipoprotein(a) inhibits angiogenesis and tumor growth by targeting c-Src phosphorylation in VEGF-induced human umbilical endothelial cells. Int J Cancer 124: 843-852.
24. Zhang X, Song Y, Wu Y, Dong Y, Lai L, et al. (2011) Indirubin inhibits tumor growth by antitumor angiogenesis via blocking VEGFR2-mediated JAK/STAT3 signaling in endothelial cell. Int J Cancer 129: 2502-2511.
25. Kok TW, Yue PY, Mak NK, Fan TP, Liu L, et al. (2005) The anti-angiogenic effect of sinomenine. Angiogenesis 8: 3-12.
26. Cho SG, Yi Z, Pang X, Yi T, Wang Y, et al. (2009) Kisspeptin-10, a KISS1-derived decapeptide, inhibits tumor angiogenesis by suppressing Sp1-mediated VEGF expression and FAK/Rho GTPase activation. Cancer Res 69: 7062-7070.
27. Jiang J, Thyagarajan-Sahu A, Krchnak V, Jedinak A, Sandusky GE, et al. (2012) NAHA, a Novel Hydroxamic Acid-Derivative, Inhibits Growth and Angiogenesis of Breast Cancer In Vitro and In Vivo. PLoS One 7: e34283.
28. Ho TC, Chen SL, Yang YC, Chen CY, Feng FP, et al. (2008) 15-deoxy-Delta(12,14)-prostaglandin J2 induces vascular endothelial cell apoptosis through the sequential activation of MAPKS and p53. J Biol Chem 283: 30273-30288.
29. Moll UM, Petrenko O, (2003) The MDM2-p53 interaction. Mol Cancer Res 1: 1001-1008.
30. Shangary S, Wang S, (2009) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49: 223-241.
31. Chene P, (2003) Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 3: 102-109.
32. Phan J, Li Z, Kasprzak A, Li B, Sebti S, et al. (2010) Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX. J Biol Chem 285: 2174-2183.
33. Riley T, Sontag E, Chen P, Levine A, (2008) Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9: 402-412.
34. Song SY, Meszoely IM, Coffey RJ, Pietenpol JA, Leach SD, (2000) K-Ras-independent effects of the farnesyl transferase inhibitor L-744,832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells. Neoplasia 2: 261-272.
35. Klein C, Vassilev LT, (2004) Targeting the p53-MDM2 interaction to treat cancer. Br J Cancer 91: 1415-1419.
36. Ivana Scovassi A, Diederich M, (2004) Modulation of poly(ADP-ribosylation) in apoptotic cells. Biochem Pharmacol 68: 1041-1047.
37. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, et al. (2000) Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288: 1053-1058.
38. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M, (2002) Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277: 3247-3257.
39. Kapoor M, Hamm R, Yan W, Taya Y, Lozano G, (2000) Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation. Oncogene 19: 358-364.
40. Lees-Miller SP, Sakaguchi K, Ullrich SJ, Appella E, Anderson CW, (1992) Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol Cell Biol 12: 5041-5049.
41. Xie S, Wang Q, Wu H, Cogswell J, Lu L, et al. (2001) Reactive oxygen species-induced phosphorylation of p53 on serine 20 is mediated in part by polo-like kinase-3. J Biol Chem 276: 36194-36199.
42. Sionov RV, Coen S, Goldberg Z, Berger M, Bercovich B, et al. (2001) c-Abl regulates p53 levels under normal and stress conditions by preventing its nuclear export and ubiquitination. Mol Cell Biol 21: 5869-5878.
43. Villalonga-Planells R, Coll-Mulet L, Martinez-Soler F, Castano E, Acebes JJ, et al. (2011) Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. PLoS One 6: e18588.
44. Zaslavsky A, Baek KH, Lynch RC, Short S, Grillo J, et al. (2010) Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood 115: 4605-4613.
45. Hamsa TP, Kuttan G (2010) Harmine inhibits tumour specific neo-vessel formation by regulating VEGF, MMP, TIMP and pro-inflammatory mediators both in vivo and in vitro. Eur J Pharmacol.
46. Kumari SR, Mendoza-Alvarez H, Alvarez-Gonzalez R, (1998) Functional interactions of p53 with poly(ADP-ribose) polymerase (PARP) during apoptosis following DNA damage: covalent poly(ADP-ribosyl)ation of p53 by exogenous PARP and noncovalent binding of p53 to the M(r) 85,000 proteolytic fragment. Cancer Res 58: 5075-5078.
47. Raj D, Liu T, Samadashwily G, Li F, Grossman D, (2008) Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis 29: 194-201.
48. Wang L, Dutta SK, Kojima T, Xu XL, Khosravi-Far R, et al. (2007) Neuropilin-1 Modulates p53/Caspases Axis to Promote Endothelial Cell Survival. PLoS One 2.
49. Montero E, Abreu C, Tonino P, (2008) Relationship between VEGF and p53 expression and tumor cell proliferation in human gastrointestinal carcinomas. J Cancer Res Clin Oncol 134: 193-201.